Effect of zoledronic acid 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: Results from horizon-pft

被引：0
|
作者：
Cauley, J. [1 ]
Black, D. [2 ]
Boonen, S. [3 ]
Cummings, S. [2 ]
Delmas, P. [4 ]
Eriksen, E. F. [5 ]
Hu, H. [6 ]
Eastell, R. [7 ]
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Leuven Univ Ctr Metab Bone Dis, Div Geriatr Med, Louvain, Belgium
[4] Univ Lyon 1, F-69365 Lyon, France
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Pharma Corp, E Hanover, NJ USA
[7] No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：523 / 523
页数：1
相关论文
共 50 条
  • [41] The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
    Black, D. M.
    Reid, I. R.
    Cauley, J.
    Boonen, S.
    Cosman, F.
    Leung, P.
    Lakatos, P.
    Man, Z.
    Cummings, S.
    Hue, T.
    Ruzycky, M.
    Martinez, Ruvie Lou Maria
    Su, G.
    Bucci-Rechtweg, C. M.
    Eastell, R.
    BONE, 2011, 48 : S91 - S91
  • [42] Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial
    G. Cai
    H. I. Keen
    L. V. Host
    D. Aitken
    L. L. Laslett
    T. Winzenberg
    A. E. Wluka
    D. Black
    G. Jones
    Osteoporosis International, 2020, 31 : 1741 - 1747
  • [43] Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial
    Cai, G.
    Keen, H. I.
    Host, L. V.
    Aitken, D.
    Laslett, L. L.
    Winzenberg, T.
    Wluka, A. E.
    Black, D.
    Jones, G.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (09) : 1741 - 1747
  • [44] TIME TO ONSET OF ANTI-FRACTURE EFFICACY AND PERSISTENCE OF EFFECT OF ZOLEDRONIC ACID 5 MG IN WOMEN WITH OSTEOPOROSIS OR RECENT HIP FRACTURE
    Black, D. M.
    Boonen, S.
    Bucci-Rechtweg, C.
    Mesenbrink, P.
    Eastell, R.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S272 - S272
  • [45] Time to onset of anti-fracture efficacy and persistence of effect of zoledronic acid 5 mg in women with osteoporosis or recent hip fracture
    Black, D. M.
    Eastell, R.
    Boonen, S.
    Bucci-Rechtweg, C.
    Mesenbrink, P.
    BONE, 2009, 44 (02) : S241 - S242
  • [46] The Addition of Once-Yearly Zoledronic Acid 5mg to Non-Bisphosphonate Treatment for Osteoporosis Reduced Fractures in Postmenopausal Women: The Horizon-Pivotal Fracture Trial
    Reid, David
    Delmas, Pierre
    Eastell, Richard
    Boonen, Steven
    Cummings, Steven
    Palermo, Lisa
    Cauley, Jane
    Recknor, Chris
    Cosman, Felicia
    Mesenbrink, Peter
    Krieginan, Andrey
    Eriksen, Erik
    Black, Dennis
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2008, 15 (06): : 1204 - 1205
  • [47] The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
    Black, Dennis M.
    Reid, Ian R.
    Cauley, Jane A.
    Cosman, Felicia
    Leung, Ping Chung
    Lakatos, Peter
    Lippuner, Kurt
    Cummings, Steven R.
    Hue, Trisha F.
    Mukhopadhyay, Amitava
    Tan, Monique
    Aftring, R. Paul
    Eastell, Richard
    JOURNAL OF BONE AND MINERAL RESEARCH, 2015, 30 (05) : 934 - 944
  • [48] Increased integral bone mineral density (BMD) of the hip with once-yearly zoledronic acid 5 mg (ZOL): Quantitative computed tomography data (QCT) from the horizon-pft trial
    Eastell, R.
    Lang, T.
    Boonen, S.
    Cummings, S.
    Delmas, P. D.
    Cauley, J.
    Horowitz, Z.
    Kerzberg, E.
    Leung, P.
    Man, Z.
    Mesenbrink, P.
    Eriksen, E. F.
    Black, D.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S54 - S55
  • [49] Relationship between change in total hip BMD in response to zoledronic acid 5 mg and pre-treatment change in total hip BMD: The HORIZON-PFT Extension study
    Eastell, R.
    Palermo, L.
    Boonen, S.
    Cosman, F.
    Reid, I.
    Cummings, S.
    Black, D.
    BONE, 2012, 50 : S55 - S55
  • [50] EFFECT OFA ONCE-YEARLY ZOLEDRONIC ACID ON BMD AND THE RISK OF FALLING IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Lin, H.
    Xu, T.
    Fan, L.
    Yang, H.
    Chen, X.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S649 - S650
12345